Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-10

Clinical Trial Update: Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study of B244 in mild to moderate atopic dermatitis completed, results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • B244

Snippet

Sponsor: AOBiome LLC | Conditions: Atopic Dermatitis Eczema | Phase 2 | Status: COMPLETED | Results posted: 2022-10-10